vildagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - sykursýki, tegund 2 - lyf notuð við sykursýki - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).
vildagliptin/metformin krka filmuhúðuð tafla 50 mg/1000 mg
krka d.d. novo mesto* - metforminum hýdróklóríð; vildagliptinum inn - filmuhúðuð tafla - 50 mg/1000 mg
vildagliptin/metformin krka filmuhúðuð tafla 50 mg/850 mg
krka d.d. novo mesto* - vildagliptinum inn; metforminum hýdróklóríð - filmuhúðuð tafla - 50 mg/850 mg
icandra (previously vildagliptin / metformin hydrochloride novartis)
novartis europharm limited - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).
eucreas
novartis europharm limited - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.
zomarist
novartis europharm limited - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - lyf notuð við sykursýki - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.
sitagliptin/metformin medical valley filmuhúðuð tafla 50mg/1000 mg
medical valley invest ab - metforminum hýdróklóríð; sitagliptinum hýdróklóríð - filmuhúðuð tafla - 50mg/1000 mg
sitagliptin/metformin sandoz filmuhúðuð tafla 50/1000 mg
sandoz a/s* - metforminum hýdróklóríð; sitagliptinum hýdróklóríð - filmuhúðuð tafla - 50/1000 mg
sitagliptin/metformin zentiva (sitagliptin metformin zentiva) filmuhúðuð tafla 50 mg/1000 mg
zentiva k.s.* - metforminum hýdróklóríð; sitagliptinum hýdróklóríð - filmuhúðuð tafla - 50 mg/1000 mg
sitagliptin/metformin zentiva (sitagliptin metformin zentiva) filmuhúðuð tafla 50 mg/850 mg
zentiva k.s.* - metforminum hýdróklóríð; sitagliptinum hýdróklóríð - filmuhúðuð tafla - 50 mg/850 mg